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Introduction: Dacomitinib (PF-00299804), an irreversible pan-
human epidermal growth factor receptor ([HER]-1/EGFR, HER-2, 
and HER-4) tyrosine kinase inhibitor, demonstrated antitumor activ-
ity in Western patients with non–small-cell lung cancer (NSCLC) at 
a dose of 45 mg once daily. We report data from a phase I/II, mul-
ticenter, open-label study of Korean patients with refractory KRAS 
wild-type adenocarcinoma NSCLC (defined as patients with evi-
dence of disease progression during or within 6 months of treatment 
with chemotherapy and gefitinib or erlotinib).
Methods: The phase I dose-finding portion identified the recom-
mended phase II dose (RP2D) in Korean patients, evaluated safety, 
and characterized the pharmacokinetics of dacomitinib. In the phase 
II portion, patients received dacomitinib at the RP2D. The primary 
end point was progression-free survival at 4 months (PFS
4m
).
Results: Twelve patients enrolled in phase I, and 43 patients enrolled 
in phase II at the RP2D of 45 mg once daily. In phase II, PFS
4m
 was 
47.2% (95% confidence interval [CI], 31.6–61.3; one-sided p-value 
= 0.0007). Median PFS was 15.4 weeks (95% CI, 9.7–17.6); median 
overall survival was 46.3 weeks (95% CI, 32.7–not reached); and 
the objective response rate was 17.1% (95% CI, 7.2–32.1). Common 
treatment-related adverse events were dermatitis acneiform, diar-
rhea, and paronychia; there were no treatment-related grade 4 or 
5 adverse events. Pharmacokinetic parameters of dacomitinib in 
Korean patients were similar to those reported in Western patients. 
By patient report, NSCLC symptoms “cough” and “pain” showed 
improvement within 3 weeks of initiating treatment.
Conclusions: Dacomitinib was well tolerated and had antitumor 
activity in Korean patients with NSCLC who had previously pro-
gressed on chemotherapy and an epidermal growth factor receptor 
tyrosine kinase inhibitor.
Key Words: Dacomitinib, Non–small-cell lung cancer, Erlotinib, 
Gefitinib, Refractory.
(J Thorac Oncol. 2014;9: 1523–1531)
Patients with non–small-cell lung cancer (NSCLC) have limited treatment options after failure of reversible epider-
mal growth factor receptor (HER1/EGFR) inhibitors, erlotinib 
or gefitinib, and chemotherapy. Dacomitinib (PF-00299804) 
is an orally bioavailable, irreversible, small-molecule inhibi-
tor of HER1/EGFR, human epidermal growth factor recep-
tor 2 (HER2), and HER4 tyrosine kinases.1 Dacomitinib has 
preclinical activity in NSCLC models with EGFR-activating 
mutations, and with the EGFR “gatekeeper” resistance T790M 
mutation, present in 50% of patients with EGFR mutations 
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who develop gefitinib or erlotinib resistance.1–5 Clinical trials 
in Western patients have identified a recommended phase II 
dose (RP2D) of dacomitinib of 45 mg once daily (QD), with 
associated antitumor activity in NSCLC.6
KRAS is a downstream effector of EGFR signal transduc-
tion; tumors with activated KRAS might therefore be expected to 
be resistant to EGFR inhibition.7,8 Indeed, KRAS mutation is a 
negative predictor of response to EGFR tyrosine kinase inhibitors 
(TKIs).9 In addition, primary oncogenic mutations in NSCLC 
are usually mutually exclusive.10 EGFR mutations have been 
reported in approximately 50% of Asian patients,11 and KRAS 
mutations have been reported in 5% to 10% of Asian patients 
with adenocarcinoma.12 A selection strategy that includes only 
patients with KRAS wild-type tumors would enrich for a popula-
tion with over a 50% chance of harboring an EGFR mutation 
and be more likely to respond to targeted therapy.
We report the results of a Korean multicenter, open-label, 
single-arm, phase I/II trial of single-agent dacomitinib in Asian 
patients with KRAS wild-type advanced NSCLC. Patients had 
received erlotinib or gefitinib and more than or equal to one reg-
imen of chemotherapy, with progressive disease (PD) during or 
less than or equal to 6 months after treatment (NCT00553254). 
The aim was to establish the RP2D of dacomitinib in this set-
ting and to assess whether clinical activity in refractory NSCLC 
warrants further development in this population.
PATIENTS AND METHODS
Patient Population
Eligible patients were more than or equal to 18 years with 
histologically or cytologically confirmed metastatic (stage 3B/4) 
adenocarcinoma NSCLC, which was KRAS wild type. Patients 
had received more than or equal to one regimen of chemother-
apy (including ≥1 platinum-based therapy) and erlotinib or gefi-
tinib with evidence of PD less than or equal to 6 months after 
treatment. Patients had Eastern Cooperative Oncology Group 
performance status (ECOG PS) 0–1 (phase I cohort) and 0–2 
(phase II cohort); those with known active brain metastases were 
excluded. Further details regarding inclusion/exclusion crite-
ria are available (see supplementary materials, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A629).
Trial Design and Treatment
In the setting described above, the phase I primary objec-
tive was to define the RP2D of dacomitinib and evaluate safety 
and tolerability. The phase II primary objective was to assess 
the antitumor efficacy of single-agent dacomitinib adminis-
tered QD, using progression-free survival (PFS) at 4 months 
(PFS
4m
). As evolving published data13 suggested that PFS and 
overall survival (OS) can be improved with EGFR TKI treat-
ment despite a low objective response rate (ORR),14 the original 
phase II primary end point, ORR, was amended to PFS
4m
 as this 
was considered a more clinically meaningful efficacy end point.
Phase I secondary objectives included characteriza-
tion of single- and multiple-dose pharmacokinetics (PK) of 
dacomitinib; analysis of pre- and post-treatment serum levels 
of HER2 and EGFR extracellular domains, and exploration 
of relationships between changes in these serum proteins and 
clinical response to dacomitinib; and description of prelimi-
nary antitumor activity using Response Evaluation Criteria in 
Solid Tumors version 1.0 (RECIST v 1.0).15 Phase II second-
ary objectives included confirmation of the safety and toler-
ability of dacomitinib; assessment of antitumor activity using 
ORR, duration of overall response, PFS at 6 months, and OS 
at 6 months; characterization of multiple-dose PK of dacomi-
tinib; analysis of pre- and post-treatment serum levels of the 
soluble HER2 and EGFR extracellular domains; and explo-
ration of patient-reported outcomes (PROs) of health-related 
quality of life and disease/treatment-related symptoms.
In phase I, successive cohorts of six patients received 
escalating doses of oral dacomitinib, starting at 30 mg QD. If 
less than two of six patients (i.e., <33%) experienced a dose-
limiting toxicity (DLT) at 30 mg QD, the next six patients 
received 45 mg QD. A DLT comprised any of the following 
during the first 21 days of cycle 1 (graded according to the 
National Cancer Institute Common Terminology Criteria for 
Adverse Events, version 3.0): any treatment-related grade 
greater than or equal to 3 nonhematologic toxicity (including 
grade 3 or 4 nausea, vomiting, or diarrhea despite adequate/
maximal medical intervention and/or prophylaxis); treatment-
related toxicity that delayed dacomitinib dosing by more than 
14 days; treatment-related grade 4 neutropenia for more than 
or equal to 5 days or febrile neutropenia; or treatment-related 
grade 4 thrombocytopenia or bleeding requiring platelet trans-
fusion. The maximum tolerated dose was the highest dose 
resulting in first-cycle DLTs in less than two of six patients, 
assessed up to a maximum dose of 45 mg.
During phase I, a single lead-in dose of dacomitinib 
was administered between completion of screening and day 
−9. Assigned treatment was then initiated on day 1. In phase 
II, patients received the RP2D of dacomitinib determined in 
phase I; dosing started on day 1 of each cycle without a lead-
in period. Dacomitinib was administered at approximately 
the same time each day (with water, on an empty stomach) in 
21-day cycles (defined for the purposes of scheduling treatment 
visits). Patients continued dacomitinib until unacceptable tox-
icity, disease progression, withdrawal from the trial, or death. 
Dose reductions or delays were permitted throughout the trial 
for treatment-related grade 3 or 4 toxicity or for intolerable 
grade 2 toxicity despite optimal supportive care. Treatment 
delay or interruption for more than 2 consecutive weeks due to 
dacomitinib-related toxicity resulted in the patient being with-
drawn from the trial. All patients were followed for survival 
for at least 12 months; patients who discontinued treatment for 
reasons other than PD were followed until disease progression 
or the start of new cancer treatment, whichever occurred first.
This trial was approved by an Institutional Review 
Board/Independent Ethics Committee at each participating 
center. All patients provided written, signed informed consent 
before entry into the trial.
Evaluation of Safety and Tolerability
The RP2D was determined through evaluation of DLTs, 
as described above. Safety and tolerability were assessed 
using standard methodology up to the 28-day period after 
final administration of dacomitinib or until all drug-related 
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toxicities had resolved or were deemed irreversible, which-
ever was later. Adverse events were graded using National 
Cancer Institute Common Terminology Criteria for Adverse 
Events version 3.0. For all patients receiving a lead-in dose 
in phase I, electrocardiograms and vital signs were assessed 
at screening and 6, 24, and 144 hours postdose; physical and 
skin exams, hematology, coagulation panel, blood chemistry, 
and urinalysis were also performed at screening and 24 hours 
and 144 hours (6 days) postdose.
Evaluation of Antitumor Activity
PFS
4m
 was defined as the proportion of patients who were 
alive without disease progression at 4 months relative to all 
patients enrolled. Evaluation of antitumor activity was based on 
objective tumor assessments (RECIST version 1.0),15 per inves-
tigator assessment, performed within 4 weeks before the start of 
treatment and every 6 weeks on study or when PD was suspected.
Evaluation of Patient-Reported Outcomes
PROs were measured using the 30-question European 
Organization for Research and Treatment of Cancer Quality 
of Life Questionnaire (EORTC-QLQ-C30), its 13-ques-
tion lung cancer module (LC13),16–18 and the 10-question 
Dermatology Life Quality Index.19 All questionnaires were 
validated in Korean and completed before any clinical assess-
ments at screening (baseline), on day 1 of cycle 2 and each 
subsequent cycle, and at the end of treatment. Completion 
rates were calculated as the number of subjects completing 
the assessment divided by the total number of subjects eligible 
for the assessment.
Pharmacokinetic Analyses
Plasma samples were collected at prespecified intervals 
pre- and postdose throughout the trial (see supplementary 
materials for further details, Supplemental Digital Content 
1, http://links.lww.com/JTO/A629). Plasma dacomitinib con-
centrations were determined at Alta Analytical Laboratory 
(El Dorado Hills, CA) using a validated, sensitive high-per-
formance liquid chromatography—atomic pressure ionization 
tandem mass spectrometric method in compliance with Pfizer 
standard operating procedures.
Pharmacokinetic parameters were derived using a non-
compartmental approach (eNCA version 2.2, Pfizer Inc., 
Groton, CT), and after a single-dose administration (D-9) 
included maximum observed plasma concentration (C
max
), 
time to C
max
 (T
max
), terminal elimination half-life (t
1/2
), area 
under the plasma concentration–time curve from 0 to 24 hours 
after a single dose (AUC
24
), area under the plasma concen-
tration–time curve from 0 to infinity (AUC
inf
), and apparent 
oral clearance (CL/F). Parameters derived after multiple-dose 
administration (C1D14) included C
max
, T
max
, CL/F, area under 
the plasma concentration–time curve from 0 to 24 hours at 
steady state (AUC
tau
), predose trough concentration (C
trough
), 
and accumulation ratio (R
ac
, the ratio of AUC
tau
 to AUC
24
). 
Predose trough concentrations (C
trough
) on day 1 of cycles 2 
to 4 together with C
trough
 concentrations on cycle 1 day 14 are 
summarized by visit.
Pharmacodynamic (Biomarker) Analysis
In phases I and II, serum levels of soluble protein 
biomarkers (HER2 and EGFR extracellular domains) were 
assessed at baseline and before dosing on day 1 of cycle 1 
and every two cycles thereafter. Potential correlations between 
biomarker levels and efficacy, response, and tumor shrinkage 
were investigated.
Statistical Analyses
No specific statistical hypothesis testing for safety, PK, 
and efficacy was planned for the phase I portion of the trial. 
The sample size was determined empirically; it was expected 
that approximately 18 patients would be enrolled. For the 
phase II portion of the trial, the Fleming single-stage design 
(amended from a Simon two-stage optimal design) was used 
to test the null hypothesis that PFS
4m
 was less than or equal to 
25%. Enrollment of 42 patients was planned. The type I error 
was 10%, and the design had 80% power to reject the null 
hypothesis when the true PFS
4m
 rate was 40%.
Baseline characteristics and time-to-event efficacy end 
points were evaluated in the intent-to-treat population. Safety 
was evaluated in the as-treated population and response 
assessed in the response-evaluable population.
RESULTS
Patient Characteristics and Disposition
Between February 2008 and July 2008, 12 patients were 
enrolled in phase I; 43 patients were subsequently enrolled in 
phase II (September 2008–March 2010). Most patients were 
heavily pretreated (58.3% of patients in phase I had received 
two regimens, and 60.5% of patients in phase II had received >3 
prior regimens). All patients had received prior erlotinib or gefi-
tinib, and three patients had received more than one prior TKI 
(Table 1); for the overall population (N = 55, phases I and II), the 
most recent prior EGFR inhibitor was erlotinib, 26 patients, and 
gefitinib, 29 patients; 61.5% of patients who received prior erlo-
tinib and 20.7% who received prior gefitinib started study drug 
within 3 months of discontinuing the prior EGFR TKI. Overall, 
the median duration of the most recent prior erlotinib/gefitinib 
regimen was 4.6 months (range, 0.9–37.2 months) for erlotinib 
and 6.9 months (range, 0.9–40.4 months) for gefitinib. There 
were eight partial responses (PRs) to prior erlotinib and 12 PRs 
to prior gefitinib. Most patients (83.3% of phase I and 65.1% of 
phase II) were never smokers. Molecular screening of tumor tis-
sue was required to confirm KRAS wild type. EGFR and HER2 
mutation status was not required. Among 14 patients with EGFR-
mutant NSCLC, EGFR mutation location was unspecified in 
four (28.6%) patients, three (21.4%) had exon 19 deletion, three 
(21.4%) had exon 21 mutation, two (14.3%) had exon 20 inser-
tion mutation (a known EGFR inhibitor resistance mutation), one 
(7.1%) had exon 20/21 + T790M (a known EGFR inhibitor resis-
tance mutation), and one (7.1%) had exon 18/21 dual mutation.
Maximum Tolerated Dose
No DLTs were observed up to a dose of 45 mg QD, 
which was confirmed as the RP2D in Korean patients 
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with KRAS wild-type advanced NSCLC, consistent with 
Western studies.
Safety and Tolerability
The incidence of all-grade treatment-related adverse 
events in the overall population (N = 55) was 53 (96.4%). The 
most common treatment-related adverse events were dermati-
tis acneiform (81.8%), diarrhea (78.2%), paronychia (63.6%), 
stomatitis (45.5%), and palmar–plantar erythrodysesthesia 
syndrome (32.7%) (Table 2). Most frequent treatment-related 
grade 3 adverse events (all occurring in the phase II cohort, i.e., 
45 mg (n = 43)) were diarrhea (n = 6; 14.0%), paronychia (n = 
4; 9.3%), and dermatitis acneiform (n = 2; 4.7%). Three treat-
ment-related hematologic adverse events (all occurring in the 
phase II cohort) included hemoglobin (n = 1; 2.4%) and lym-
phocytes (n = 2; 4.8%). No patients had treatment-related grade 
4 or 5 adverse events. Serious adverse events were experienced 
by 10 patients (phase I, one patient; phase II, nine patients); 
only one serious adverse event (one patient with diarrhea during 
phase II) was considered to be related to study treatment.
No patient discontinued for treatment-related adverse 
events. Most adverse events resulting in temporary discontin-
uation of treatment or dose reduction were treatment-related 
grade 2 or 3 diarrhea or skin events that subsequently resolved. 
There were no treatment-related deaths. The median duration 
of treatment was 85.0 days in phase I and 97.0 days in phase 
II. Three patients (25.0%) in phase I and 21 patients (48.8%) 
in phase II had a missed dose, and 0 and 15 patients (34.9%) 
required a dose reduction in phase I and II, respectively.
Efficacy
Progression-free survival
The primary efficacy objective of the study was met; 
the estimated PFS
4m
 in phase II was 47.2% (95% confidence 
interval [CI], 31.6–61.3), with a 1-sided p-value of 0.0007 for 
H
0
: PFS
4m
 less than or equal to 25%. This was associated with 
a median PFS of 15.4 weeks (95% CI, 9.7–17.6) (Fig. 1A) 
and an estimated PFS rate at 6 months of 24.8% (95% CI, 
12.9–38.7). Median PFS for all patients (N = 55) was 13.7 
weeks (95% CI, 11.4–17.6). Fourteen patients (25.5%) had an 
EGFR mutation (two patients in phase I starting from 30 mg 
and 12 patients in phase II). The 12 patients in phase II whose 
tumors were EGFR mutation positive had a median PFS of 
15.4 weeks (95% CI, 5.4–35.6).
Overall survival
In phase II, OS was analyzed when 25 patients (58.1%) 
had died; median OS was 46.3 weeks (95% CI, 32.7–not 
reached) (Fig. 1B). The probability of survival at 6 and 12 
months was 80.7% (95% CI, 65.1–89.9) and 39.1% (95% CI, 
24.0–53.9), respectively.
OS was analyzed in the overall population (N = 55) 
when 34 patients (61.8%) had died; median OS was 47.1 
weeks (95% CI, 32.7–60.6).
Best overall response
There were 41 response-evaluable patients in phase 
II (two patients without an on-study tumor assessment were 
excluded from the analysis; one with EGFR mutation in exon 
21 and one with unknown EGFR status), of whom seven 
(17.1%) achieved a PR, including two with EGFR mutation 
and five with unknown EGFR status (see Supplementary 
Table 1 for additional details, Supplemental Digital Content 
1, http://links.lww.com/JTO/A629); 21 (51.2%) had stable 
disease (SD), including two patients with an unconfirmed PR 
(per RECIST 1.0 definition of confirmation). The clinical ben-
efit rate (complete response, PR or SD ≥24 weeks) in phase 
TABLE 1.  Patient Baseline Characteristics by Study Phase
Characteristic Phase I (n = 12) Phase II (n = 43)
Median age, yr (range) 51.5 (31–78) 59.0 (40–72)
Gender, n (%)
  Male 3 (25.0) 20 (46.5)
  Female 9 (75.0) 23 (53.5)
Smoking history, n (%)
  Never 10 (83.3) 28 (65.1)
  Current 0 1 (2.3)
  Ex-smokera 2 (16.7) 14 (32.5)
Prior systemic treatment, n (%)
  1 regimen 0 0
  2 regimens 7 (58.3) 6 (14.0)
  3 regimens 1 (8.3) 11 (25.6)
  >3 regimens 4 (33.3) 26 (60.5)
Prior EGFR inhibitors, n (%)b
  Erlotinib 5 (41.7) 22 (51.2)
  Gefitinib 7 (58.3) 22 (51.2)
  Vandetanib 0 1 (2.3)
Median duration of most recent prior EGFR inhibitor, mo (range)
  Erlotinib 4.8 (0.9–14.5) 4.6 (1.0–37.2)
  Gefitinib 2.9 (0.9–10.9) 7.6 (0.9–40.4)
Prior response
  Erlotinib 1 PR, 2 SD, 2 PD 7 PR, 10 SD, 4 PD
  Gefitinib 2 PR, 3 SD, 2 PD 10 PR, 8 SD, 4 PD
ECOG performance status, n (%)
  0 2 (16.7) 11 (25.6)
  1 10 (83.3) 29 (67.4)
  2 0 3 (7.0)
EGFR mutation status, n (%)
  Wild type 3 (25.0) 3 (7.0)
  Mutant 2 (16.6) 12 (27.9)
  Unknown 7 (58.3) 28 (65.1)
HER2 mutation status, n (%)
  Wild type 0 9 (20.9)
  Mutant 0 1 (2.3)
  Unknown 12 (100.0) 33 (76.7)
a>100 cigarettes/cigars/pipes over lifetime.
bFor phase II, three patients received more than one EGFR TKI regimen: one patient 
received two nonconsecutive regimens of erlotinib; one patient received erlotinib before 
receiving gefitinib (these regimens were nonconsecutive); and one patient received 
vandetanib followed by a consecutive regimen of gefitinib.
ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor 
receptor; EGFR, epidermal growth factor receptor gene; PD, progressive disease; PR, 
partial response; SD, stable disease; TKI, tyrosine kinase inhibitor.
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II was 29.3% (95% CI, 16.1–45.5) (see Supplementary Table 
2, Supplemental Digital Content 1, http://links.lww.com/JTO/
A629). Median duration of response for the seven patients 
with a PR in phase II was 60.0 weeks. A further two patients 
in phase I treated at 45 mg had a PR (see Supplementary Table 
1, Supplemental Digital Content 1, http://links.lww.com/JTO/
A629). Two case histories for patients with PRs are shown in 
Supplementary Figures 1 (Supplemental Digital Content 2, 
http://links.lww.com/JTO/A630) and 2 (Supplemental Digital 
Content 3, http://links.lww.com/JTO/A631).
Overall, 13 of 20 patients with known EGFR status had 
EGFR mutation and were also response-evaluable patients; 
of these, two patients (15.4%) had a PR (95% CI, 1.9–45.4), 
eight (61.5%) had SD (two patients receiving 30 mg in phase 
I), and three (23.1%) had PD as best overall response. In 
phase II, 19 of 40 patients (47.5%) with a baseline and more 
than or equal to one postbaseline tumor measurement had 
some degree of target lesion decrease from baseline (Fig. 2). 
Among the 19 patients with tumor shrinkage, one (5.3%) and 
six (31.6%) had EGFR wild-type and EGFR-mutant tumors, 
respectively, and 12 (63.2%) had tumors of unknown EGFR 
status. One patient with prolonged SD (249 days) as best 
overall response had the secondary EGFR resistance mutation 
T790M and experienced tumor shrinkage of 31.0% (Fig. 2). 
Of 20 patients with PR to prior erlotinib/gefitinib, response 
to dacomitinib included PR (n = 6), SD (n = 12), PD (n = 1), 
and indeterminate (n = 1). EGFR mutation status for these 
patients is provided in Supplementary Table 3 (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A629). Of the 10 
patients with SD of more than or equal to 24 weeks’ duration 
in response to erlotinib or gefitinib, three had a PR, four had 
SD, and three had PD in response to dacomitinib.
Patient-reported outcomes
Completion rates for the EORTC-QLQ-C30/-LC13 
and Dermatology Life Quality Index questionnaires were 
high (≥95%). Mean EORTC-QLQ-C30/-LC13 assessment 
TABLE 2.  Treatment-Related Adverse Events (Occurring in ≥10% of Patients in Overall Population; n = 55) and Hematology 
Laboratory Values by Maximum CTCAE Grade (All Cycles)
Phase I (N = 12) Phase II (N = 43)
Total (N = 55)Grade 1 Grade 2 Grade 3 Totala Grade 1 Grade 2 Grade 3 Totala
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Treatment-related adverse events
  Dermatitis  
  acneiform
4 (33.3) 6 (50.0) 0 10 (83.3) 14 (32.6) 19 (44.2) 2 (4.7) 35 (81.4) 45 (81.8)
  Diarrhea 5 (41.7) 3 (25.0) 0 8 (66.7) 19 (44.2) 10 (23.3) 6 (14.0) 35 (81.4) 43 (78.2)
  Paronychia 4 (33.3) 2 (16.7) 0 6 (50.0) 13 (30.2) 12 (27.9) 4 (9.3) 29 (67.4) 35 (63.6)
  Stomatitis 4 (33.3) 1 (8.3) 0 5 (41.7) 11 (25.6) 8 (18.6) 1 (2.3) 20 (46.5) 25 (45.5)
  Palmar–plantar  
  erythrodysesthesia 
syndrome
2 (16.7) 3 (25.0) 0 5 (41.7) 12 (27.9) 1 (2.3) 0 13 (30.2) 18 (32.7)
  Dry skin 0 1 (8.3) 0 1 (8.3) 5 (11.6) 11 (25.6) 0 16 (37.2) 17 (30.9)
  Pruritus 1 (8.3) 1 (8.3) 0 2 (16.7) 11 (25.6) 3 (7.0) 1 (2.3) 15 (34.9) 17 (30.9)
  Decreased  
  appetite
2 (16.7) 0 0 2 (16.7) 10 (23.3) 3 (7.0) 0 13 (30.2) 15 (27.3)
  Mucosal  
  inflammation
2 (16.7) 3 (25.0) 0 5 (41.7) 5 (11.6) 2 (4.7) 0 7 (16.3) 12 (21.8)
  Fatigue 0 0 0 0 6 (14.0) 1 (2.3) 1 (2.3) 8 (18.6) 8 (14.5)
  Nausea 3 (25.0) 0 0 3 (25.0) 5 (11.6) 0 0 5 (11.6) 8 (14.5)
  Erythematous  
  rash
1 (8.3) 0 0 1 (8.3) 2 (4.7) 3 (7.0) 0 5 (11.6) 6 (10.9)
Phase I (N = 12) Phase II (N = 42)b
Total (N = 54)Grade 1 Grade 2 Grade 3 Totalc Grade 1 Grade 2 Grade 3 Totalb
Hematology laboratory values by maximum CTCAE grade
  Hemoglobin 7 (58.3) 1 (8.3) 0 8 (66.7) 20 (47.6) 6 (14.3) 1 (2.4) 27 (64.3) 35 (64.8)
  Lymphocytes 7 (58.3) 1 (8.3) 0 8 (66.7) 27 (64.3) 5 (11.9) 2 (4.8) 34 (81.0) 42 (77.8)
  Neutrophils 2 (16.7) 0 0 2 (16.7) 1 (2.4) 0 0 1 (2.4) 3 (5.6)
  Platelets 2 (16.7) 0 0 2 (16.7) 4 (9.5) 0 0 4 (9.5) 6 (11.1)
  White blood cells 1 (8.3) 1 (8.3) 0 2 (16.7) 2 (4.8) 2 (4.8) 0 4 (9.5) 6 (11.1)
aNo grade 4 or 5 treatment-related adverse events were reported.
bOne patient had a missing postbaseline laboratory assessment and so was excluded.
cNo grade 4 hematologic abnormalities.
CTCAE, Common Toxicity Criteria for Adverse Events.
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scores at baseline and changes during study treatment rela-
tive to baseline are summarized and compared with previ-
ously published normative values in Supplementary Table 4 
(Supplemental Digital Content 1, http://links.lww.com/JTO/
A629).20 During study treatment, patients with radiographic 
disease control reported improvement in lung cancer symp-
toms of cough, pain in chest, and pain in arm/shoulder rela-
tive to baseline scores (Fig. 3A). Adverse impact of diarrhea 
and sore mouth peaked at cycle 2, day 1 (week 3), and sub-
sequently improved over time (Fig. 3B). Skin toxicity events 
had a longer time to onset, with a peak at cycle 5, day 1, and 
improved thereafter (Fig. 3C). Qualitatively, these results indi-
cated that, at its worst, treatment-related skin toxicity had a 
“moderate effect” on patients’ life over the prior week.19 Mean 
baseline scores for the above six items are listed in Figure 3D 
with previously published normative values.20
Pharmacokinetics
PK parameters of dacomitinib after single (day −9) and 
multiple doses in patients receiving consecutive doses for more 
than or equal to 14 days are summarized in Supplementary 
Table 5 (Supplemental Digital Content 1, http://links.lww.
com/JTO/A629). After single-dose administration (day −9), 
observed median T
max
 was 8.0 hours and 5.0 hours for 30 and 
45 mg doses, respectively. After multiple-dose administra-
tion (C1D14), observed median T
max
 was 5.0 and 6.1 hours for 
30 mg and 45 mg dosing, respectively. Mean apparent clearance 
was 33.6 and 36.0 liter/hr after administration of a single oral 
dose of 30 and 45 mg, respectively. Mean R
ac
 was 5.3 and 5.7 for 
the 30 and 45 mg doses, respectively. Dose-normalized param-
eters such as C
max
, AUC
inf
, and AUC
tau
, after a single dose or at 
steady state, were similar in 30 mg and 45 mg dosing cohorts 
(Supplementary Fig. 3, Supplemental Digital Content 4, http://
links.lww.com/JTO/A632). Plasma concentration–time plots 
after single and multiple doses are shown in Figure 4A and 
4B, respectively. As seen in previous studies, plasma exposure 
of dacomitinib increased with dose, with a higher exposure at 
45 mg compared with 30 mg dosing after single and multiple 
oral dosing. Terminal elimination of dacomitinib was similar 
after a single oral dose of 30 or 45 mg.6,21
Pharmacodynamics
Mean ratios to baseline of serum levels of EGFR and 
HER-2 were largely unchanged in all cycles of the phase I 
study. Similarly, ratios to baseline of these biomarkers were not 
significantly changed at all cycles during phase II. No correla-
tions were observed between changes in levels of these serum 
proteins and clinical response to dacomitinib (data not shown).
DISCUSSION
Dacomitinib was well tolerated in this Korean patient 
population; no DLTs were observed up to a dose of 45 mg 
QD, which was therefore confirmed as the RP2D. The RP2D 
and the observed safety profile were consistent with reports 
from Western studies6,22,23 and a study of unselected Japanese 
patients, the majority of whom had NSCLC.21 No discontinu-
ations due to treatment-related adverse events, and no grade 4 
FIGURE 2.  Best percent change from baseline in target 
lesion as assessed by RECIST in the phase II portion. N = 40: 
One patient with progressive disease in nontarget lesion but 
no target lesion measurement and two patients without on-
study tumor scan were excluded. †Two patients had >30% 
reduction at one post-treatment assessment, but PR was not 
confirmed on a follow-up assessment and responses were 
classified as SD per RECIST v1.0. RECIST, Response Evaluation 
Criteria in Solid Tumors v1.0; PR, partial response; SD, stable 
disease.
FIGURE 1.  Kaplan–Meier plot of (A) progression-free 
survival and (B) overall survival in the phase II portion, as 
enrolled.
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or 5 adverse events, were reported in Korean patients. Adverse 
events (primarily skin and gastrointestinal toxicities) were 
consistent with the expected toxicities of EGFR TKIs,24–26 
although the incidence of paronychia (63.6%) reported here 
was somewhat higher than has been noted in other studies of 
irreversible pan-HER TKIs in the refractory, second/third-
line, and first-line settings.22,23,27,28 However, given the rela-
tively small sample size of the current study, it is not possible 
to draw any wider conclusions from this observation.
Encouraging antitumor activity was observed with 
dacomitinib in heavily pretreated Korean patients with 
refractory NSCLC. The median PFS of 15.4 weeks com-
pares favorably with a phase II study in Western patients, 
where the PFS for KRAS wild-type adenocarcinoma was 12 
weeks.29 In another single-arm phase II study, LUX-Lung 4, 
the irreversible EGFR/HER1 and HER2 inhibitor afatinib 
(BIBW 2992) demonstrated a PFS of 4.4 months and ORR 
of 8.2%30; differences from the present study included eligi-
bility criteria of at least 12 weeks of prior TKI (thus enrich-
ing for an EGFR-mutant population) and conduct only in 
Japan. The LUX-Lung 1 phase IIb/III study evaluated afa-
tinib in patients with NSCLC (PS 0–2) and disease progres-
sion after one or two lines of chemotherapy and erlotinib 
or gefitinib.27 This study revealed improvement in median 
PFS of 3.3 months (95% CI, 2.79–4.40) for afatinib plus 
best supportive care and a hazard ratio of 0.38 (p < 0.0001 
relative to placebo). However, there was no improvement 
in median OS (afatinib: 10.8 months [95% CI, 10.0–12.0], 
placebo: 12.0 months [95% CI, 10.2–14.3]; hazard ratio, 
1.08; 95% CI, 0.86–1.35; p = 0.74). These results suggest 
that irreversible inhibition of the HER family receptors may 
improve PFS without improvement in OS in unselected 
FIGURE 3.  Mean change from baseline in (A) lung cancer symptoms of cough, pain in chest, and pain in arm or shoulder 
(EORTC QLQ-C13); (B) class-related adverse events of diarrhea (EORTC QLQ-C30) and sore mouth (EORTC QLQ-LC13); (C) 
skin toxicity by total scores on DLQI (Dermatology Life Quality Index). Baseline scores and equivalent normative values for the 
respective symptoms are listed in panel (D). Higher scores indicate higher levels of symptoms or a higher degree of impairment 
of functioning; lower scores indicate fewer symptoms or a lower degree of impairment of functioning. EORTC scales are scored 
from 0 to 100; DLQI total scores range from 0 to 30. SD, standard deviation.
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patients with refractory NSCLC that have failed to respond 
to both EGFR TKIs and chemotherapy.
The impact on patients of treatment-related side effects 
and therapy-mediated modulation of disease symptoms 
are increasingly recognized as key elements of cancer care, 
particularly in late-stage, noncurative settings.31 Patients in 
this clinical trial were less symptomatic at baseline than the 
EORTC reference population.20 However, they still reported 
improvement in lung cancer symptoms of cough and pain in 
chest/arm/shoulder, beginning as early as the third week of 
therapy. These improvements appeared to be durable while 
patients remained on treatment. According to PRO, gastroin-
testinal class-effect toxicities peaked early in therapy (cycle 2, 
week 3), but were manageable and improved over time with 
intervention, despite minimal treatment guidelines for diar-
rhea, mucositis, and skin toxicity in this trial. This is the first 
study to report the impact of EGFR TKI-related skin toxic-
ity exclusively in Korean patients. Although many patients 
reported skin toxicity symptoms at baseline, skin toxicity had 
a longer time to peak onset (cycle 5, week 12) than gastroin-
testinal toxicity. At its worst, skin toxicity was shown to have 
a “moderate effect” on patients’ lives over the prior week. 
Ongoing phase III studies include a recommendation for pro-
active and early interventions to reduce the frequency and 
severity of dermatologic and gastrointestinal adverse events, 
and a toxicity prevention study is ongoing (NCT01465802).
Dacomitinib systemic exposure increased with increasing 
dose in this study, with PK parameters increasing dose-propor-
tionally at the dose levels evaluated. The observed R
ac
 and dose-
normalized parameters such as C
max
, AUC
inf
, and C
trough
 suggest 
that dacomitinib has linear kinetics after single- and multiple-dose 
administration of 30 mg and 45 mg doses. Furthermore, PK param-
eters observed in Korean patients after single- and multiple-dose 
administration of dacomitinib in this study seem similar to prior 
observations in studies with Western and Japanese patients.6,21–23
At the time the current study was designed, available 
data suggested a possible relationship between tumor response 
to gefitinib and serum levels of soluble EGFR, with no such 
relationship apparent for soluble HER2.32 Subsequently, a ret-
rospective analysis noted that pretreatment level of soluble 
EGFR more than 55 ng/ml was significantly associated with 
prolonged survival,33 whereas high pretreatment level of solu-
ble HER2 was a negative prognostic indicator.34 More recently, 
tumor-specific soluble EGFR isoforms have been identified, 
raising the possibility that highly specific assays are required 
to evaluate potential biomarkers.35 The exploratory analyses 
of the present study did not support a role for either soluble 
EGFR or soluble HER2 as biomarkers of dacomitinib efficacy, 
despite encouraging disease control. Further prospective stud-
ies are needed to evaluate potential biomarkers, particularly 
as diminishing levels of soluble HER2 in individual patients 
responding to dacomitinib are not unprecedented.36
CONCLUSION
In summary, dacomitinib demonstrated encouraging dis-
ease control and an acceptable safety profile in Korean patients 
with KRAS wild-type adenocarcinoma of the lung. However, it 
has been reported37 that recently completed phase III studies of 
dacomitinib in unselected patients as second/third-line treat-
ment and for refractory NSCLC failed to meet the primary end 
point (data currently unpublished). In this present study, patient 
selection was directed by clinical, histologic, and molecular 
parameters, resulting in a high likelihood of the presence of 
an EGFR-sensitizing mutation. The results reported here sup-
port robust biomarker collection to support evaluation of clini-
cal trial outcomes in order to identify the subset of patients 
with refractory NSCLC who are most likely to benefit. A phase 
III trial is underway to determine the efficacy and safety of 
dacomitinib versus gefitinib in previously untreated patients 
with activating mutations in exon 19 or 21 (ARCHER 1050; 
NCT01774721).
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FIGURE 4.  Median dacomitinib plasma concentration–time 
plots on cycle 0 day −9 (30 mg and 45 mg, single dose) (A); 
and on cycle 1, day 14 (30 mg and 45 mg, multiple dose), for 
dose-compliant patients (B).
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